Eribulin treatment for patients with metastatic breast cancer: The UK Experience - A Multicenter Retrospective Study

Mariam Jafri (Lead / Corresponding author), Hartmut Kristeleit, Vivek Misra, Mark Baxter, Samreen Ahmed, Apurna Jegannathen, Ankit Jain, David Maskell, Urmila Barthakur, Gwenllian Edwards, Harriet S. Walter, Richard Walshaw, Madeha Khan, Annabel Borley, Daniel Rea

Research output: Contribution to journalArticlepeer-review

47 Downloads (Pure)


Introduction: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK.

Methods: Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS).

Results: Among 577 patients analyzed, the median age was 56 years, and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261-315), and the PFS was 117 days (95% CI: 105-129). The median OS was higher among older patients (≥65 vs. <65 years: 325 days [95% CI: 264-385] vs. 285 days [95% CI: 252-317]; p = 0.028). The median OS was also higher in patients who received eribulin after fewer prior lines of chemotherapy (≤2 vs. >2 prior: 328 days [95% CI: 264-385] vs. 264 days [95% CI: 229-298]; p = 0.042).

Discussion/Conclusion: These retrospective data suggest that eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings, which, while predictable, supports consideration of eribulin as a second-line treatment option.

Original languageEnglish
Pages (from-to)666-673
Number of pages8
Issue number12
Early online date31 Aug 2022
Publication statusPublished - Dec 2022


  • eribulin
  • observation study
  • real-world
  • metastatic breast cancer
  • older adults
  • second-line
  • Observation study
  • Second-line treatment
  • Eribulin
  • Real-world data
  • Metastatic breast cancer
  • Older adults

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Eribulin treatment for patients with metastatic breast cancer: The UK Experience - A Multicenter Retrospective Study'. Together they form a unique fingerprint.

Cite this